Drug Trial Radar · NCT00050934
Pediatric Epilepsy Study
Last checked: Nov 19, 2026Latest source record: Nov 23, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
132
Actual
Start
Jun 2002
Primary completion
Jun 2004
Study completion Jun 2004
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jan 1, 2003
Design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Who can join
- All sexes, from 1 month, up to 3 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety and effectiveness of oxcarbazepine (Trileptal) as add-on therapy in the treatment of partial seizures in pediatric patients 1 month to 3 years of age.
Conditions
- Epilepsy
- Epilepsies, Partial
Interventions
oxcarbazepineDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- change in seizure frequency/24 hours (during the last 72 hours in the Treatment Phase compared to Baseline)
Locations
30 sites in 4 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Mobile, Alabama
Site not named
Los Angeles, California
Site not named
Los Angeles, California
Site not named
Madera, California
Site not named
Orange, California
Site not named
Wilmington, Delaware
Site not named
Miami, Florida
Site not named
Tampa, Florida
Site not named
Atlanta, Georgia
Site not named
Boise, Idaho
Site not named
Ann Arbor, Michigan
Site not named
Duluth, Minnesota
Site not named
Saint Paul, Minnesota
Site not named
Chesterfields, Missouri
Site not named
Buffalo, New York
Site not named
New York, New York
Site not named
New York, New York
Site not named
Akron, Ohio
Site not named
Cincinnati, Ohio
Site not named
Cleveland, Ohio
Site not named
Portland, Oregon
Site not named
Philadelphia, Pennsylvania
Site not named
Fort Worth, Texas
Site not named
Houston, Texas
Site not named
Norfolk, Virginia
Brigadeiro Hospital
Sao Paulo - SP, Brazil
Site not named
Kehl-Kork, Germany
Site not named
Kiel, Germany
Novartis
Mexico City, Mexico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.